التفاصيل البيبلوغرافية
| العنوان: |
Repositioning: the fast track to new anti-malarial medicines? |
| المؤلفون: |
Lotharius, Julie, Gamo-Benito, Francisco Javier, Angulo-Barturen, Iñigo, Clark, Julie, Connelly, Michele, Ferrer-Bazaga, Santiago, Parkinson, Tanya, Viswanath, Pavithra, Bandodkar, Balachandra, Rautela, Nikhil, Bharath, Sowmya, Duffy, Sandra, Avery, Vicky M., Möhrle, Jörg J., Guy, R. Kiplin, Wells, Timothy |
| المصدر: |
Malaria Journal; 2014, Vol. 13 Issue 1, p1-34, 34p, 3 Diagrams, 7 Charts, 4 Graphs |
| مصطلحات موضوعية: |
DRUG therapy for malaria, MALARIA treatment, ANTIMALARIALS, PHARMACOKINETICS, DRUG approval |
| الشركة/الكيان: |
GLAXOSMITHKLINE |
| مستخلص: |
Background: Repositioning of existing drugs has been suggested as a fast track for developing new antimalarial agents. The compound libraries of GlaxoSmithKline (GSK), Pfizer and AstraZeneca (AZ) comprising drugs that have undergone clinical studies in other therapeutic areas, but not achieved approval, and a set of US Food and Drug Administration (FDA)-approved drugs and other bio-actives were tested against of Plasmodium falciparum blood stages. Methods Molecules were tested initially against erythrocytic co-cultures of P. falciparum to measure proliferation inhibition using one of the following methods: SYBR®I dye DNA staining assay (3D7, K1 or NF54 strains); [3H] hypoxanthine radioisotope incorporation assay (3D7 and 3D7A strain); or 4',6-diamidino-2-phenylindole (DAPI) DNA imaging assay (3D7 and Dd2 strains). After review of the available clinical pharmacokinetic and safety data, selected compounds with low µM activity and a suitable clinical profile were tested in vivo either in a Plasmodium berghei four-day test or in the P. falciparum Pf3D70087/N9 huSCID 'humanized' mouse model. Results: Of the compounds included in the GSK and Pfizer sets, 3.8% (9/238) had relevant in vitro anti-malarial activity while 6/100 compounds from the AZ candidate drug library were active. In comparison, around 0.6% (24/3,800) of the FDA-approved drugs and other bioactives were active. After evaluation of available clinical data, four investigational drugs, active in vitro were tested in the P. falciparum humanized mouse model: UK-112,214 (PAFH1 inhibitor), CEP-701 (protein kinase inhibitor), CEP-1347 (protein kinase inhibitor), and PSC-833 (p-glycoprotein inhibitor). Only UK-112,214 showed significant efficacy against P. falciparum in vivo, although at high doses (ED90 131.3 mg/kg [95% CI 112.3, 156.7]), and parasitaemia was still present 96 hours after treatment commencement. Of the six actives from the AZ library, two compounds (AZ-1 and AZ-3) were marginally efficacious in vivo in a P. berghei model. Conclusions: Repositioning of existing therapeutics in malaria is an attractive proposal. Compounds active in vitro at µM concentrations were identified. However, therapeutic concentrations may not be effectively achieved in mice or humans because of poor bio-availability and/or safety concerns. Stringent safety requirements for anti-malarial drugs, given their widespread use in children, make this a challenging area in which to reposition therapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Malaria Journal is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder